Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1
Finanzen,
Almirall S.A. (BME:ALM), a global biopharmaceutical company focused on medical dermatology, today announced the presentation of…